Balyasny Asset Management L.P.
Position in ALLO — Allogene Therapeutics, Inc.
CIK 1218710
Chicago, IL
Position in ALLO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,886,071
+$2,761,132 QoQ
Shares Held
1,182,816
+2105.8% QoQ
Ownership
0.342%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALLO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Balyasny Asset Management L.P. holds $2,351,657,469 across 178 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
1,665,102 | $221,008,988 | |
| 2 | INSM |
INSMED Inc
|
1,326,430 | $141,423,966 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,230,052 | $91,614,272 | |
| 4 | ABVX |
Abivax S.A.
|
603,840 | $80,467,718 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
145,005 | $72,028,333 | |
| 6 | TNGX |
Tango Therapeutics, Inc.
|
2,016,379 | $63,032,007 | |
| 7 | CYTK |
Cytokinetics Inc
|
711,676 | $60,627,678 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
1,054,613 | $60,344,955 |
All Filings in ALLO
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,886,071 | 1,182,816 | Shares | Sole | 2026-05-15 | |
| 2024-06-30 | $124,939 | 53,622 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $95,286 | 21,317 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $50,493 | 15,730 | Shares | Sole | 2024-02-14 | |
| 2022-12-31 | $1,059,160 | 168,388 | Shares | Other | 2023-02-14 | |
| 2022-09-30 | $447,972 | 41,479 | Shares | Other | 2022-11-15 | |
| 2021-03-31 | $3,466,742 | 98,208 | Shares | Sole | 2021-05-17 | |
| 2020-09-30 | $5,545,594 | 147,059 | Shares | Sole | 2020-11-16 | |
| No filing history on record for this holder in this stock. | ||||||